EIM
PTCT icon

Essex Investment Management’s PTC Therapeutics PTCT Stock Holding History

Essex Investment Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-17,157
Closed -$458K – 325
2015
Q3 		$458K Buy
+17,157
New +$734K 0.08% 236

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Essex Investment Management's PTCT Position: Q4 2015 in Review

Essex Investment Management sold out of PTC Therapeutics (PTCT) in Q4 2015, closing a stake of 17,157 shares — an estimated $458K sold.

Essex Investment Management first reported a position in PTCT in Q3 2015 and held it in 1 quarter. The position peaked at $458K in Q3 2015. 141 funds tracked by Wall St. Rank hold PTCT as of Q4 2015.

  • Essex Investment Management reported no remaining PTC Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Essex Investment Management sold 17,157 PTC Therapeutics shares in Q4 2015, an estimated $458K.
  • Essex Investment Management first reported a position in PTC Therapeutics in Q3 2015 and held it in 1 quarter.
  • Essex Investment Management's PTC Therapeutics position peaked at $458K in Q3 2015.
  • 141 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2015.

Based on Essex Investment Management's 13F filing for Q4 2015, filed 26 Jan 2016.